
Study
Blinded RCTs
Non−blinded RCTs
ROR
CI (95%)
Weight
Short−term mortality assessment time−point
Hua, 2016 (59) 9 5 1.23 [0.78; 1.95] 3.5%
Gebistorf, 2016 (58) 4 5 1.19 [0.68; 2.11] 2.3%
Dushianthan, 2019 (56) 3 3 1.00 [0.32; 3.15] 0.6%
Lewis, 2018 (64) 4 6 1.00 [0.84; 1.20] 22.3%
Lewis, 2018 (64) 8 2 0.95 [0.46; 1.98] 1.4%
Chu, 2018 (53) 3 10 0.94 [0.49; 1.79] 1.8%
Drewry, 2017 (55) 6 2 0.89 [0.49; 1.62] 2.0%
Szakmany, 2012 (76) 9 2 0.88 [0.20; 3.90] 0.3%
Rochwerg, 2018 (74) 30 6 0.86 [0.44; 1.68] 1.7%
Mesgarpour, 2017 (70) 5 2 0.84 [0.13; 5.30] 0.2%
Fujii, 2018 (57) 1 4 0.79 [0.21; 3.03] 0.4%
Lewis, 2018 (64) 5 6 0.78 [0.62; 0.98] 14.4%
Mesgarpour, 2017 (70) 12 6 0.73 [0.44; 1.21] 2.8%
McIntyre, 2018 (69) 7 14 0.72 [0.51; 1.01] 6.2%
Alhazzani, 2013 (49) 1 2 0.54 [0.20; 1.45] 0.8%
Bo, 2011 (52) 7 2 0.44 [0.15; 1.30] 0.6%
Wang, 2017 (78) 3 2 0.26 [0.06; 1.19] 0.3%
Random effects model 0.88 [0.79; 0.99] 61.6%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.66
Long−term mortality assessment time−point
Putzu, 2019 (72) 8 8 1.31 [0.64; 2.66] 1.5%
Liberati, 2009 (65) 4 13 1.28 [0.92; 1.76] 7.0%
Qiu, 2013 (73) 12 3 1.25 [0.67; 2.33] 1.9%
Shah, 2016 (75) 1 2 1.23 [0.03; 53.15] 0.1%
Kun−Ming, 2014 (62) 18 12 1.12 [0.62; 2.02] 2.1%
Manzanares, 2013 (66) 6 6 1.10 [0.53; 2.31] 1.3%
Allingstrup, 2016 (50) 8 18 1.06 [0.73; 1.52] 5.5%
Barbateskovic, 2019 (51) 15 11 1.00 [0.69; 1.44] 5.3%
Cortegiani, 2016 (54) 15 3 0.99 [0.51; 1.89] 1.7%
Zampieri, 2015 (79) 3 2 0.92 [0.26; 3.25] 0.5%
Tan, 2010 (77) 8 7 0.91 [0.34; 2.42] 0.8%
Liberati, 2009 (65) 9 4 0.81 [0.44; 1.50] 1.9%
Manzanares, 2016 (68) 10 7 0.77 [0.43; 1.38] 2.2%
Lewis, 2016 (63) 5 1 0.72 [0.17; 3.07] 0.4%
Zarychanski, 2015 (80) 3 3 0.69 [0.29; 1.66] 1.0%
Oczkowski, 2017 (71) 2 2 0.61 [0.22; 1.65] 0.7%
Koster, 2014 (61) 9 10 0.57 [0.30; 1.09] 1.7%
Koster, 2016 (60) 3 2 0.56 [0.20; 1.55] 0.7%
Manzanares, 2016 (67) 11 7 0.49 [0.27; 0.87] 2.2%
Random effects model 0.96 [0.83; 1.10] 38.4%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.57
Random effects model 0.91 [0.84; 0.99] 100.0%
Heterogeneity: I^2 = 0%, τ^2 = 0, p = 0.70
Residual heterogeneity: I^2 = 0%, p = 0.69
0.1
0.2
0.5
1
2
5
10
Non−blinded more beneficial
Non−blinded less beneficial